navinci 产品代理

产品分类 > 科研试剂 > navinci 产品代理

navinci 产品代理

Navinci(前身为Olink Bioscience)在发明核酸和蛋白质分析技术、发现商业机会以及将成功的产品推向市场,为科学家提供研究和药物开发服务方面有着引以为傲的历史。该公司于2004年在乌普萨拉大学Ulf Landegren教授及其同事的突破性创新基础上成立,直接销售了多种产品,包括2016年被Sigma Aldrich收购的Duolink原位蛋白质检测产品线,Proseek多重面板现在被称为Olink Target,由Olink蛋白质组学公司销售。

2020年,Navinci向全世界NaveniFlex产品线的科学家推出了下一代邻近连接分析技术,这是我们的专有技术。我们现在正在迅速扩大蛋白质相互作用和翻译后修饰的原位检测,这是免疫荧光和免疫组织化学等标准技术所无法实现的。
价格: 0.00

NaveniFlex kits

Naveni pTyr Her2

Naveni pTyr EGFR

Naveni pTyr Met

Naveni pTyr PDGF-beta



Navinci (formerly Olink Bioscience), has a proud history of inventing analytic technologies for nucleic acids and proteins, identifying commercial opportunities and bringing successful products to the market to serve scientist in research and drug development. First founded in 2004 on the breakthrough innovations by Professor Ulf Landegren and colleagues at Uppsala University, the company has directly marketed a wide range of products including the Duolink in situ protein detection product line, which was acquired by Sigma-Aldrich in 2016, and Proseek multiplex panels now known as Olink Target and marketed by Olink Proteomics.

 

In 2016, Olink Bioscience became Navinci Diagnostics after the split from Olink Proteomics, which are now focused on using highly multiplexed protein biomarker analysis in circulation to improve precision medicine, and has recently been noted on Nasdaq NY.

 

Navinci has in close collaboration with Uppsala University continued to innovate the field of spatial biology with groundbreaking tools for studies of the tissue microenvironment.

 

In 2020, Navinci launched the next generation of proximity ligation assay techniques, our proprietary UnFold technology, to scientists worldwide in the NaveniFlex product line. We are now rapidly expanding our offering for in situ detection of protein interactions and post-translational modifications, not possible with standard techniques such as ImmunoFluorescence and ImmunoHistoChemistry.